Should β-blockers still be routine after myocardial infarction?

Current Opinion in Cardiology

Volumn 28, Issue 4, 2013, Pages 399-404

  Thompson, Peter L ^a,b  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

blockers; myocardial infarction; outcomes; prognosis

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; CORONARY REPERFUSION; DRUG EFFICACY; EVIDENCE BASED PRACTICE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ADRENERGIC BETA-ANTAGONISTS; HEALTH SERVICES MISUSE; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION;

EID: 84879946605     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e328361e97a     Document Type: Review

References (46)

1. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group Lancet 1986; 2:57-66.
2. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. Eur Heart J 1985; 6:199-226.
3. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myo-cardial infarction: results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med 1989; 320:618-627.
4. Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 1991; 83:422-437.
5. Van de Werf F, Janssens L, Brzostek T, et al. Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarc-tion receiving thrombolytic therapy. J Am Coll Cardiol 1993; 22:407-416.
6. Pfisterer M, Cox JL, Granger CB, et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Cor-onary Arteries. J Am Coll Cardiol 1998; 32:634-640.
7. Ibanez B, Fuster V, Macaya C, et al. Study design for the effect of METOprolol in CARDioproteCtioN during an acute myocardial Infar Ction (METOCARD-CNIC): a randomized, controlled parallel-group, observer-blinded clinical trial of early prereperfusion metoprolol administration in ST-segment elevation myocardial infarction. Am Heart J 2012; 164:473-480.
8. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318:1730-1737.
9. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366:1622-1632.
10. Al-Reesi A, Al-Zadjali N, Perry J, et al. Do beta-blockers reduce short-term mortalityfollowing acute myocardial infarction?Asystematic reviewand metaanalysis. CJEM 2008; 10:215-223.
11. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guidelinefor the Management of ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61:e78-e140.
12. Steg PG, James SK, Atar D, et al., Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myo-cardial infarction in patients presenting with ST segmentelevation. Eur Heart J 2012; 33:2569-2619.
13. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32:2999-3054.
14. Kumbhani DJ, Fonarow GC, Cannon CP, et al. Get With the Guidelines Steering Committee and Investigators. Predictors of adherence to perfor-mance measuresin patientswith acutemyocardial infarction. Am J Med 2013; 126:74; e1-e9.
15. Olomu AB, Grzybowski M, Ramanath VS, et al. American College of Cardio-logy Foundation Guidelines Applied in Practice Steering Committee. Evidence of disparity in the application of quality improvement efforts for the treatment of acute myocardial infarction: the American College of Cardiology's Guidelines Applied in Practice Initiative in Michigan. Am Heart J 2010; 159:377-384.
16. Glickman SW, Ou FS, DeLong ER, et al. Payfor performance, qualityofcare, and outcomes in acute myocardial infarction. JAMA 2007; 297:2373-2380.
17. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 casesofsuspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group Lancet 1988; 2:349-360.
18. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO Investigators N Engl J Med 1993; 329:673-682.
19. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angio-plasty in Myocardial Infarction Study Group. N Engl J Med 1993; 328:673-679.
20. A clinical trial comparing primary coronary angioplasty with tissue plasmino-gen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators N Engl J Med 1997; 336:1621-1628.
21. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of rando-mised trials of antiplatelet therapy for prevention of death, myocardial infarc-tion, and stroke in high risk patients. BMJ 2002; 324:71-86.
22. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504.
23. Yusuf S, Zhao F, Mehta SR, et al. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502.
24. Chen ZM, Jiang LX, Chen YP, et al. Additionof clopidogrel toaspirin in 45 852 patientswith acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366:1607-1621.
25. Pasotti M, Prati F, Arbustini E.The pathology of myocardial infarction inthe pre and postinterventional era. Heart 2006; 92:1552-1556.
26. Briffa T, Hickling S, Knuiman M, et al. Long term survival afterevidence based treatment of acute myocardial infarction and revascularisation: follow-up of population based Perth MONICA cohort, 1984-2005. BMJ 2009; 338:b36.
27. Peterson ED, Shah BR, Parsons L, et al. Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J 2008; 156: 1045-1055.
28. Mehta RH, Roe MT, Chen AY, et al. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. Arch Intern Med 2006; 166:2027-2034.
29. Jeger RV, Radovanovic D, Hunziker PR, et al. Urban P AMIS Plus Registry Investigators. Ten-year trends in the incidence and treatment of cardiogenic shock. Ann Intern Med 2008; 149:618-626.
30. Fox KA, Steg PG, Eagle KA, et al. GRACE Investigators. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 2007; 297:1892-1900.
31. Nauta ST, Deckers JW, van Domburg RT, Akkerhuis KM.Sex-related trends in mortality in hospitalized men and women after myocardial infarction between 1985 and 2008: equal benefit for women and men. Circulation 2012; 126:2184-2189.
32. Movahed MR, John J, Hashemzadeh M, et al. Trends in the age adjusted mortality from acute ST segment elevation myocardial infarction in the United States (1988-2004) based on race, gender, infarct location and comorbidities. Am J Cardiol 2009; 104:1030-1034.
33. Movahed MR, John J, Hashemzadeh M, Hashemzadeh M. Mortality trends for non-ST-segment elevation myocardial infarction (NSTEMI) in the United States from 1988 to 2004. Clin Cardiol 2011; 34:689-692.
34. Yeh RW, Sidney S, Chandra M, et al. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 2010; 362:2155-2165.
35. Van de Werf FJ, Topol EJ, Sobel BE. The impact of fibrinolytic therapy for ST-segment-elevation acute myocardial infarction. J Thromb Haemost 2009; 7:14-20.
36. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, et al. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90:583-612.
37. Thygesen K, Alpert JS, Jaffe AS, et al. Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012; 60:1581-1598.
38. Luepker RV, Duval S, Jacobs DR Jr, et al. The effect of changing diagnostic algorithms on acute myocardial infarction rates. Ann Epidemiol 2011; 21:824-829.
39. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366:1545-1553.
40. Wiysonge CS, Bradley H, Mayosi BM, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2007; CD002003.
41. Wiysonge CS, Bradley HA, Volmink J, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2012; CD002003; doi: 10.1002/14651858.CD002003.pub4.
42. Ozasa N, Kimura T, Morimoto T, et al. j-Cypher Registry Investigators. Lack of effectof oral beta-blockertherapy atdischargeon long-termclinical outcomes of ST-segment elevation acute myocardial infarction after primary percuta-neous coronary intervention. Am J Cardiol 2010; 106:1225-1233.
43. Bangalore S, Steg G, Deedwania P, et al. REACH Registry Investigators. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012; 308:1340-1349.
44. Lechat P, Packer M, Chalon S, et al. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebocontrolled, randomized trials. Circulation 1998; 98:1184-1191.
45. Chatterjee S, Biondi-Zoccai G, Abbate A, et al. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network metaanalysis. BMJ 2013; 346:f55; doi: 10.1136/bmj.f55.
46. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 2001; 134:550-560.